Business
Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations
CORAL GABLES, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"CORAL GABLES, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations. This position will report to the Chief Executive Officer of Catalyst. \"We are delighted to welcome Ms. Coleman to the Catalyst team. Her extensive investor relations experience in the pharmaceutical industry and insights make her uniquely qualified to support our investor relations objectives,\" said Patrick J. McEnany, Chairman and CEO of Catalyst. \"In this newly created position, Ms. Coleman will play an instrumental role in developing and implementing our investor relations program as we continue to execute our growth strategy and elevate our profile among the investment community.\" Ms. Coleman added, \"I am excited to join the Catalyst team, which has a profound commitment to developing novel medicines that address important needs for those patients living with rare diseases. I look forward to working with the team on communicating Catalyst's growth strategy and enhance its profile to help deliver long-term value for shareholders.\" Ms. Coleman joins Catalyst with more than 20 years of investor relations and corporate communications experience in the biotechnology and specialty pharmaceutical industry. Ms. Coleman has held senior investor relations leadership positions with various publicly traded companies from early-stage to commercial-stage, leading the development and execution of the investor relations strategy to broaden and strengthen relationships with the investment community. She recently served as Vice President, Investor Relations at BioXcel Therapeutics and previously held the position of Head of Investor Relations at Jubilant Pharmaceuticals, Ltd., a global integrated pharmaceutical company where she served as a member of the company's leadership team. Ms. Coleman received a B.A. degree from Bowling Green State University. About Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commer...